Palatin Technologies Files 8-K on Material Agreement

TL;DR

Palatin Tech signed a big deal on 8/14, filed 8-K on 8/18.

AI Summary

Palatin Technologies, Inc. filed an 8-K on August 18, 2025, reporting a material definitive agreement entered into on August 14, 2025. The filing also includes Regulation FD disclosures and financial statements/exhibits. Specific details of the agreement are not provided in this excerpt.

Why It Matters

This filing indicates Palatin Technologies has entered into a significant new agreement, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing reports a material definitive agreement, but the lack of specific details about the agreement's nature and terms introduces uncertainty.

Key Players & Entities

• PALATIN TECHNOLOGIES, INC. (company) — Registrant
• August 14, 2025 (date) — Date of earliest event reported
• August 18, 2025 (date) — Date of report
• 001-15543 (company) — Commission File Number
• 95-4078884 (company) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share PTN 1 NYSE American Ind
• $2.3 million — eive an upfront payment of 2.0 million ($2.3 million USD), up to 18.0 million ($20.9 million
• $20.9 million — ($2.3 million USD), up to 18.0 million ($20.9 million USD) in near-term research milestone pa
• $301.6 million — estone payments, and up to 260 million ($301.6 million USD) in success-based development, regu

Filing Documents

• ptn_8k.htm (8-K) — 31KB
• ptn_ex991.htm (EX-99.1) — 18KB
• ptn_ex991img2.jpg (GRAPHIC) — 4KB
• ptn_ex991img5.jpg (GRAPHIC) — 1KB
• 0001654954-25-009743.txt ( ) — 175KB
• ptn-20250814.xsd (EX-101.SCH) — 5KB
• ptn-20250814_lab.xml (EX-101.LAB) — 14KB
• ptn-20250814_cal.xml (EX-101.CAL) — 1KB
• ptn-20250814_pre.xml (EX-101.PRE) — 9KB
• ptn-20250814_def.xml (EX-101.DEF) — 2KB
• ptn_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 14, 2025, Palatin Technologies Inc. ("Palatin"), entered into a Research Collaboration, License and Patent Assignment Agreement (the "Agreement") with Boehringer Ingelheim International GmbH ("BI") to research, develop and commercialize first-in-class melanocortin receptor-targeted peptides developed by Palatin for the treatment of retinal diseases, including diabetic retinopathy. Under the terms of the Agreement, Palatin assigned certain patent rights to BI (the "Assigned Patents"), and Palatin will conduct collaborative research with BI at BI's expense focused on development during a two-year period, which BI has the right to extend by up to 6 months. Under the terms of the Agreement, Palatin will receive an upfront payment of 2.0 million ($2.3 million USD), up to 18.0 million ($20.9 million USD) in near-term research milestone payments, and up to 260 million ($301.6 million USD) in success-based development, regulatory, and commercial milestone payments, plus tiered royalties on net commercial sales of Products. The royalty payments are subject to reduction due to patent expiration, generic competition and payments made under certain licenses for third-party intellectual property. The Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term, unless earlier terminated. BI has the right to terminate the Agreement for any reason after a specified notice period. Each party has the right to terminate the Agreement on account of the other party's bankruptcy or material, uncured breach. The foregoing description of the Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete text of the Agreement, which will be filed with the U.S. Securities and Exchange Commission as an exhibit to the Company's Quarterly Report on Form 10-

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On August 18, 2025, BI and Palatin issued a press release announcing entering into the Agreement. The press release is furnished as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), whether made before or after the date hereof, except as expressly set forth by specific reference in such filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained therein.

Forward-Looking Statements

Forward-Looking Statements This Current Report includes forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "will" and "expected", or the negative of such terms, or other comparable terminology, and include statements about the Reverse Stock Split and the impacts, if any, on the Company's Common Stock. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due to many factors. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this Current Report, and the Company expressly disclaims any obligation or undertaking to update or revise and forward-looking statement contained herein, or to reflect any change in the Company's expectations with regard thereto or any other change in events, conditions, or circumstances, on which any such statement is based, except to the extent otherwise required by applicable law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated August 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 18, 2025 PALATIN TECHNOLOGIES, INC. /s/ Stephen T. Wills Stephen T. Wills, CPA, MST Executive Vice President, Chief Financial Officer and Chief Operating Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR